Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review

Figures & data

Figure 1. Immunohistochemical staining (IHC) of DLBCL tissue sample. IHC staining of CD5 (A). (Original magnification, *100). Positive IHC staining of CD5 (B), CD20 (C), CD79a (D), MUM1 (G), and negative staining of CD10 (E), Bcl-6 (F), MYC (H), CD3 (I). (Original magnification, *400).

Figure 2. PET/CT scan before the start of treatment (A) and after three cycles of R2-GDP (B). The yellow arrows demonstrated the lesions where abdominal masses disappeared (B).

Table 1. Outcomes of CD5+ DLBCL treated with rituximab containing chemotherapy.

Reference	Patients (n)	Initial treatment	ASCT/AlloSCT (n)	Response rate	OS	Other outcomes
Ennishi D et al, 2008^2	11	R-CHOP	—	—	2-year 45%	2-year EFS: 18%
Hyo R et al, 2010^3	11	R-CHOP, R-CHOP-like	—	—	2-year 59%	Without rituximab, 2-year OS 50%
Niitsu N et al, 2010^4	45	R-CHOP, R-CyclOBEA	—	—	4-year 63.5%	4-year PFS: 62.5%
Miyazaki K et al, 2011^5	184	R-CHOP, R-CHOP-like	19 ASCT, 2 alloSCT,	CR 80%	2-year 70%	8 patients who received
						ASCT during CR1 in sustained remission
Alinari L et al, 2016^6	102	R-CHOP, R-EPOCH, R-CHOP-HD MTX	20 ASCT, 4 alloSCT, 4 received both	ORR 85%	3-year 65%	3-year PFS 40%; median PFS 18 month
Thakral B et al, 2017^7	16	R-EPOCH	3 ASCT	CR 56%	Median OS 28.13 month; 28.5-month 62.5%	1 patient died 8 months after ASCT

ASCT: autologous stem cell transplantation; AlloSCT: allogeneic SCT; CR: complete response; ORR: overall response rate; OS: overall survival; EFS: event-free survival; PFS: progression-free survival; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-EPOCH: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CyclOBEA: rituximab, cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisone; HD: high dose; MTX: methotrexate.

Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19:1921–6. doi:10.1093/annonc/mdn392. PMID:18573805.

 PubMed Web of Science ®Google Scholar

Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, Hashimoto C, Takemura S, Taguchi J, Sakai R, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2010;28:27–32. PMID:19358143.

 PubMed Web of Science ®Google Scholar

Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21:2069–74. doi:10.1093/annonc/mdq057. PMID:20231297.

 PubMed Web of Science ®Google Scholar

Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22:1601–7. doi:10.1093/annonc/mdq627. PMID:21199885.

 PubMed Web of Science ®Google Scholar

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, et al. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91:395–9. doi:10.1002/ajh.24299. PMID:26800311.

 PubMed Web of Science ®Google Scholar

Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98:415–21. doi:10.1111/ejh.12847. PMID:28039906.

 PubMed Web of Science ®Google Scholar